ABVC.US ABVC Biopharma Inc

Healthcare Biotechnology USA Stocks
0.9700 USD
Close of Nov 13, 2026
0.7070 3.06
Market cap
USD 26.2M
P/E
-
P/B
2.54x
ROE
-11.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABVC.US undervalued?

Graham number

The Graham number of ABVC Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABVC Biopharma Inc fundamental analysis

No fundamental analysis for ABVC Biopharma Inc yet.

ABVC Biopharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABVC Biopharma Inc

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, wh…

Full company profile